pirtobrutinib
oral, reversible BTK inhibitor approved for R/R MCL, in Ph. II/III for CLL/SLL, NHL activity against CysC481 BTK mutants FDA approval, January 27, 2023 Redx, Alderly Park, UK (Loxo/Lilly)
Molecules of the Month - January 2023
oral, reversible BTK inhibitor approved for R/R MCL, in Ph. II/III for CLL/SLL, NHL activity against CysC481 BTK mutants FDA approval, January 27, 2023 Redx, Alderly Park, UK (Loxo/Lilly)
Molecules of the Month - January 2023